Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma

Ryuichi Mizuno, Go Kimura, Satoshi Fukasawa, Takeshi Ueda, Tsunenori Kondo, Hidehiko Hara, Sunao Shoji, Kent Kanao, Hayakazu Nakazawa, Kazunari Tanabe, Shigeo Horie, and Mototsugu Oya, on behalf of The Tokyo Metropolitan Study Group

1Department of Urology, School of Medicine, Keio University; 2Department of Urology, Nippon Medical School, Tokyo; 3Prostate Center and Division of Urology, Chiba Cancer Center, Chiba; 4Department of Urology, Tokyo Women’s Medical University; 5Department of Urology, Kyorin University School of Medicine; 6Department of Urology, Tokai University Hachioji Hospital; 7Department of Urology, Aichi Medical University, Nagakute; 8Department of Urology, Tokyo Women’s Medical University Medical Center East; 9Department of Urology, Juntendo University Faculty of Medicine, Tokyo, Japan

Key words
High sensitivity C-reactive protein, interleukin-8, renal cell carcinoma, sunitinib, T helper type 1 lymphocyte

Funding information
Funding for this study was provided by Pfizer.

Accepted July 7, 2017; Revised July 6, 2017; Cancer Sci 108 (2017) 1858–1863
doi: 10.1111/cas.13320

Kidney cancer, or renal cell carcinoma (RCC), arises from renal tubular epithelium. Complete surgical resection remains the only known curative treatment in the early stages; however, up to 40% of patients eventually experience disease recurrence after curative resection and one-third of patients already have metastasis at initial presentation. With the introduction of molecular targeted therapies which inhibit tumor angiogenesis, the outlook of metastatic RCC (mRCC) has been changing. Drugs that inhibit vascular endothelial growth factor (VEGF) pathway, such as bevacizumab or tyrosine kinase inhibitors (TKI), are currently considered standard care for the treatment of mRCC.

Sunitinib malate is an oral TKI that inhibits VEGF pathway. This drug is approved multinationally for the first-line treatment of mRCC. In a phase III trial, sunitinib achieved better progression-free survival (PFS) than interferon alpha in treatment-naive patients. In this trial, up to 50% of patients receiving sunitinib obtained clinical benefits in objective response (31%) or disease stabilization (48%). However, some patients experience disease progression at first evaluation, possibly owing to intrinsic resistance. Moreover, even when an initial response is obtained, nearly all patients develop resistance, known as acquired resistance.

Currently sunitinib is recommended in treatment guidelines for the first-line treatment of mRCC. The identification of patients who may obtain benefit from sunitinib has the potential to avoid unnecessary costs and adverse events. By linking aspects of the biology of RCC, many investigators have explored the use of angiogenic factors as prognostic and predictive biomarkers in mRCC; however, validated baseline predictive molecular markers to identify individuals who might benefit from sunitinib have not been found. The aim of this prospective study was to evaluate the utility of baseline immunological and inflammatory markers, besides angiogenic molecules, to predict the efficacy of sunitinib in patients with mRCC. Because RCC is considered to be an immunological and inflammatory tumor, this approach may be appropriate. For example, non-specific immunotherapy has been the mainstay of mRCC treatments and increases in immune parameters have been correlated with poor outcomes. Tumor-mediated...
inflammation is considered to play an important role in the host tumor defense response.

We investigated the capacity of baseline angiogenic and inflammatory markers in serum as well as the baseline levels of immune cells in whole blood to predict responses to sunitinib. The availability of markers that predict responses may accelerate drug selection.

Materials and Methods

Patients and methods. In this prospective multicenter study, 90 consecutive patients with favorable or intermediate Memorial Sloan-Kettering Cancer Center (MSKCC) risk features were enrolled from 18 institutions between November 2009 and August 2012. Patients 18 years of age and older were eligible for this study, if they had good Eastern Cooperative Oncology Group performance status, a life expectancy of ≥12 weeks, a histological diagnosis of predominantly clear cell carcinoma, received no systemic therapy or one regimen of cytokine therapy, had measurable metastatic disease, and adequate hematological, hepatic, renal and cardiac functions. All patients voluntarily consented to participate in this clinical and biological studies. The present study was approved by the independent ethics committee of Keio University Hospital (No 2009-94). All procedures performed in studies involving human participants were in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All patients gave written informed consent before the study.

Study design and treatment. Sunitinib was given at a starting dose of 50 mg/day in a 4-weeks-on/2-weeks-off regimen. Blood samples were collected prior to sunitinib treatment. Dose reductions were permitted based on individual safety and tolerability. Sunitinib treatment was discontinued with progression, unacceptable adverse events or physicians’ discretion. Patients were clinically assessed every 4 weeks during the treatment until week 24, and every 6 weeks thereafter. Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, tumor response was assessed 6 and 12 weeks after treatment. After week 12, response assessments were performed every 12 weeks. The primary endpoint of the current study was identification of biomarkers to predict PFS for mRCC patients treated with first-line sunitinib. Secondary endpoints of this study were to assess PFS, overall survival (OS) and tumor response as evaluated based on RECIST.

Analysis of serum biomarkers. Prior to the initiation of sunitinib, blood samples were collected from every patient and centrifuged at the speed of 400 g for 5 min. All serum samples were stored at -80°C until analyzed. Validated enzyme-linked immunosorbent assays were used to determine serum protein levels of VEGF-C, soluble VEGF receptor (sVEGFR)-2, sVEGFR-3, hepcidin, basic fibroblast growth factor (bFGF), high-sensitivity C reactive protein (hs-CRP), interleukin (IL)-6 and IL-8. All assays were performed at SRL (Tokyo, Japan).

Flow cytometry-based analyses of immune cell population. We collected peripheral blood mononuclear cells (PBMC) from 90 patients. We calculated the percentage of T helper type 1 (Th1), T helper type 2 (Th2), T helper type 0 (Th0) cells, and the Th1:Th2 cell ratio of peripheral blood. The capacity for IFN-γ and IL-4 production within the CD4 subsets were analyzed by flow cytometry. The CD4 subsets were divided based on cytokine expression pattern into IFN-γ+/IL-4− (Th1) cells and IFN-γ−/IL-4+ (Th2) cells. We also calculated the percentage of regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSC). Treg cells were identified as CD4+CD25+FoxP3+ cells. PBMC were stained with antibodies to human CD4, CD25 and FoxP3 to identify Treg cells. MDSC were identified as CD14+CD15+CD33+HLA-DRlow cells. Cells were stained with antibodies to human CD14, CD15, CD33 and HLA-DR to identify MDSC. All results are shown as the percentage of positive cells in all PBMC. All assays were performed at SRL.

Statistical analysis. Statistical analyses focused on the investigation of baseline angiogenic, immunological and inflammatory markers as possible biomarkers. The relationship between each marker and efficacy (clinical benefit/progression) was tested using a logistic regression analysis. A receiver operating characteristics (ROC) analysis was used to see the relationships between tumor response and possible biomarkers, as previously described. The Kaplan–Meier method estimates the probability of survival. The prognostic effect of each marker on PFS or OS was investigated with Cox’s proportional-hazards regression model. In all analyses, a P-value of <0.05 were considered significant.

Results

This study group comprised 90 patients. The patient characteristics are summarized in Table 1. The median follow-up was 21 months (range 2–86 months). Among 90 patients treated with sunitinib, 56 (62.2%) patients received subsequent therapy. A total of 24 patients (42.8%) subsequently received everolimus; 15 (26.8%), 8 (14.8%) and 6 (8.9%) patients received axitinib, temsirolimus and sorafenib, respectively. The remaining patients received pazopanib (n = 1; 1.8%), interferon (n = 1; 1.8%) or sorafenib plus interferon (n = 1; 1.8%) during sunitinib treatment. Four (4.6%) and 17 (19.6%) patients were assessed as complete response (CR) and partial response (PR), respectively. Twenty-four (27.6%) patients achieved stable disease (SD) for more than 6 months. Forty-two patients (48.3%) were assessed as PD or SD for less than 6 months. Three patients were considered not assessable for efficacy. The objective response rate (CR and PR) and clinical benefit rate (CR, PR and SD ≥ 6Mo) for sunitinib treatment were 24.2 and 51.8%, respectively. During subsequent treatment, 1 (1.8%), 4 (7.1%), 36 (64.3%) and 13 (23.2%) patients were assessed as CR, PR, SD and PD, respectively. Two patients were considered not assessable for efficacy of subsequent treatment. The estimated median PFS for sunitinib and subsequent therapy were 8.4 (95% CI 6.5–13.1) and 5.1 (95% CI 2.8–6.5) months, respectively (Fig. 1a). The estimated median OS was 31.1 months (95% CI 17.4–42.8), respectively (Fig. 1b).

Table 1. Patient characteristics

| Characteristics                  | Values    |
|---------------------------------|-----------|
| Patients (number)               | 90        |
| Age (year, median range)        | 65 (31–79) |
| Gender (number, male/female)    | 71/19     |
| ECOG performance status (number)| 0: 77, 1: 11, 2: 2 |
| MSKCC risk group               | Favorable: 21, Intermediate: 69 |
Markers predicting sunitinib efficacy

Among the angiogenic, inflammatory and immunological markers analyzed, baseline levels of IL-6, IL-8, hs-CRP and MDSC were significantly lower in patients with clinical benefits compared with its counterparts, respectively. However, no significant differences were found for the other markers tested (Table 2). The areas under the ROC curves for hs-CRP, IL-6, IL-8 and MDSC as predictive markers of sunitinib were 0.603, 0.612, 0.591 and 0.558, respectively (Fig. 2).

In univariate Cox regression model analysis using the continuous value for each marker, baseline IL-8, hs-CRP and %Th1 cells significantly correlated with PFS, respectively (Table 3). On-treatment hypertension (P < 0.0001, hazard ratio = 0.161, 95% CI 0.084–0.319) and %Th1 cells (P = 0.0081, unit risk = 0.954, 95% CI 0.920–0.988) independently predicted PFS for sunitinib treatment.

In univariate Cox regression model analysis, baseline sVEGFR-3, hs-CRP and MDSC significantly correlated with OS, respectively (Table 4). On-treatment hypertension, longer sunitinib treatment period and longer subsequent treatment period predicted better OS, respectively (Table 4). A multivariate analysis identified MDSC (P < 0.0001, unit risk = 1.062, 95% CI 1.033–1.087) independently predicted OS (Table 4). When baseline markers and on-treatment markers were analyzed together, on-treatment hypertension (P < 0.0001, hazard ratio = 0.161, 95% CI 0.084–0.319) and %Th1 cells (P = 0.0081, unit risk = 0.954, 95% CI 0.920–0.988) independently predicted PFS for sunitinib treatment.

Table 2. Association between each marker and efficacy of sunitinib using a logistic regression analysis

| Markers      | Clinical benefit | PD±SD±6Mo | P value |
|--------------|------------------|----------|---------|
| VEGF-C       | 2209 ± 1195      | 2048 ± 1185 | 0.4647  |
| VEGF-R2      | 9618 ± 2285      | 8824 ± 2179 | 0.2059  |
| VEGF-R3      | 48.5 ± 18.5      | 52.6 ± 18.9 | 0.2898  |
| Hepcidine    | 112 ± 84         | 121 ± 67  | 0.2467  |
| bFGF         | 11.1 ± 3.9       | 11.4 ± 3.2 | 0.0695  |
| hs-CRP       | 14 181 ± 31 030  | 35 499 ± 40 256 | 0.0023* |
| IL-6         | 13.8 ± 41.2      | 17.4 ± 22.8 | 0.0012* |
| IL-8         | 8.5 ± 10.1       | 23.6 ± 38.4 | 0.0039* |
| %Th1 T cells | 24.6 ± 9.5       | 21.5 ± 9.3  | 0.0593  |
| %Th2 T cells | 3.7 ± 1.8        | 4.2 ± 2.4   | 0.3914  |
| Th1/Th2 ratio| 8.9 ± 7.8        | 7.5 ± 7.3   | 0.1628  |
| MDSC         | 5.8 ± 5.1        | 11.6 ± 12.5 | 0.0260* |
| Treg         | 2.9 ± 1.2        | 2.9 ± 1.0   | 0.7602  |

*Statistically significant.

Discussion

With increases in the number of treatment options currently available for mRCC, researchers and clinicians now face the question of how to maximize patient benefits based on the drugs available. Although treatment guidelines that recommend appropriate drugs according to evidence from the findings of clinical trials have been established (http://www.nccn.org/), biomarkers to recommend the most appropriate agent for each patient are warranted to maximize efficacy and to avoid unnecessary toxicities. In the present study, patients with low or intermediate risk features were evaluated for multiple baseline serum factors as well as immunological markers with the aim of identifying an informative and potentially prognostic patient profile. The present results strongly indicate baseline hs-CRP and IL-8 could predict poor PFS. We also demonstrated that some immunological markers, like MDSC or %Th1 cells, possess the ability to predict progresses and responses.

C reactive protein, which is an acute phase protein, is mainly produced by hepatocytes and has been widely used as a marker of systemic inflammation. Elevation in CRP is often observed in advanced cancers. Furthermore, high pretreatment levels of CRP often predict poor response to systemic treatment in advanced cancer patients. This implies that an underlying inflammatory mechanism would play some role in forming resistance to systemic therapy. The reasons for CRP elevations in cancer patients are not clearly understood.
understood; however, several possible mechanisms have been suggested to explain the association between cancer and increased CRP levels.\(^{15}\) One possible explanation might be that tumor growth causes inflammation around the tumor, thereby elevating the level of CRP.\(^{16,17}\) Alternatively, chronic inflammation, for which CRP is useful in monitoring, may cause cancer progression. In addition, inflammatory cytokines may facilitate cancer progression by promoting cancer cell growth and proliferation. The whole family of IL-6 type cytokine is known to induce production of acute phase proteins, including CRP, in hepatocytes. Because IL-6 acts as an intracrine growth factor in RCC, an increase in serum CRP might be induced by IL-6 produced from RCC. Among the large number of inflammatory markers, hs-CRP, which accurately measures lower levels of serum CRP than traditional CRP assays, might be the most extensively studied biomarker of low grade inflammation, especially in cardiovascular diseases.\(^{18}\) More recently, hs-CRP elevations have been

![Graph showing ROC curves for prediction of clinical benefit in 90 mRCC patients treated with sunitinib.](image)

**Table 3.** Univariate and multivariate Cox regression analyses of potential baseline factors affecting progression-free survival

| Markers (continuous) | Univariate | Multivariate |
|----------------------|------------|--------------|
|                      | \( P \) value | \( P \) value | Unit risk | 95% CI      |
| VEGF-C               | 0.3289     |              |           |             |
| VEGF-R2              | 0.5206     |              |           |             |
| VEGF-R3              | 0.1754     |              |           |             |
| Hepcidine            | 0.1321     |              |           |             |
| bFGF                 | 0.5446     |              |           |             |
| hs-CRP               | 0.0125\(^*\) | 0.0075       | 1.000     | 1.000–1.000 |
| IL-6                 | 0.8825     |              |           |             |
| IL-8                 | 0.0388\(^*\) | 0.0470       | 1.011     | 1.000–1.022 |
| %Th1 T cells         | 0.0172\(^*\) | 0.0329       | 0.960     | 0.924–0.997 |
| %Th2 T cells         | 0.2743     |              |           |             |
| Th1/Th2 ratio        | 0.1248     |              |           |             |
| MDSC                 | 0.2255     |              |           |             |
| Treg                 | 0.9051     |              |           |             |

\(^*\)Statistically significant. CI, confidence interval.

**Table 4.** Univariate and multivariate Cox regression analyses of potential baseline factors affecting overall survival

| Markers (continuous) | Univariate | Multivariate |
|----------------------|------------|--------------|
|                      | \( P \) value | \( P \) value | Unit risk | 95% CI      |
| VEGF-C               | 0.0506     |              |           |             |
| VEGF-R2              | 0.2055     |              |           |             |
| VEGF-R3              | 0.0464\(^*\) |          |           |             |
| Hepcidine            | 0.2219     |              |           |             |
| bFGF                 | 0.5446     |              |           |             |
| hs-CRP               | 0.0011\(^*\) |          |           |             |
| IL-6                 | 0.7330     |              |           |             |
| IL-8                 | 0.0964     |              |           |             |
| %Th1 T cells         | 0.1800     |              |           |             |
| %Th2 T cells         | 0.1694     |              |           |             |
| Th1/Th2 ratio        | 0.2107     |              |           |             |
| MDSC                 | <0.0001\(^*\) | <0.0001     | 1.062     | 1.033–1.087 |
| Treg                 | 0.9051     |              |           |             |

\(^*\)Statistically significant. CI, confidence interval.
associated with cancer progression and an increased risk of cancer mortality. Indeed, several studies have tried to reveal the correlation between chronic low grade systemic inflammation and cancer. The present study investigated the correlation of baseline hs-CRP, which can detect low-grade inflammation, with prognosis and found that this inflammatory marker has prognostic value in mRCC patients treated with sunitinib. Moreover, multivariate Cox analysis revealed that hs-CRP and IL-8 were independent indices to predict shorter PFS, which suggests that, besides inflammation-based resistance reflected by hs-CRP, IL-8 signaling system would independently contribute to formation of resistance to sunitinib.

IL-8, also known as CXCL8, is a potent pro-inflammatory cytokine. Besides its central role in inflammation, IL-8 induces angiogenesis by directly interacting with endothelial cells. IL-8 is also known to be an autocrine growth factor for cancer cells, including RCC. IL-8 is one of the most frequently detected cytokines in RCC. Thus, IL-8 produced from RCC cells might play a crucial role in developing clinical features of RCC, such as positive inflammatory reactions, hypervascularity and resistance to immunotherapy. In addition, a previous study reported that neutralizing antibodies to IL-8 increased the anti-angiogenic effect of sunitinib in RCC xenograft models, which implies roles of IL-8 in alternative pathways utilized by cancers to escape from sunitinib. Thus, it was not surprising when increased baseline serum IL-8 level predicted resistance to sunitinib. Several relationships have been detected between polymorphisms in IL-8 genes and the anti-angiogenic therapeutic outcomes of mRCC patients. A relationship has also been reported between the variant genotype of IL-8 and reduced OS in mRCC patients treated with pazopanib or sunitinib.

Some immunological markers may predict responses to sunitinib because RCC are known to have immunological features. Cytokine therapy was the standard of care before the advent of targeted drugs and a novel class of immunotherapeutic agents called checkpoint inhibitors is currently being tested for their application to the treatment of mRCC. In the present study we demonstrated that baseline MDSC, which can suppress T cell and natural killer cell function, could predict poor OS in mRCC patients; however, this was not surprising because previous studies proposed that MDSC would play some role in developing resistance to sunitinib treatment. We also demonstrated potential relationships between the baseline proportions of T cell subsets and the efficacy of sunitinib in mRCC patients. Th cells are classified functionally into two main types, Th1 and Th2 cells, which are antagonistic to each other. Th1 cells can secrete interferon-gamma, IL-2, tumor necrosis factor-alpha, to promote macrophages toward an M1 phenotype, further promoting cell-mediated immunity through cytotoxic T lymphocyte activation as well as Th1 responses. Th2 cells mainly secrete IL-4, IL-5, IL-9, IL-10 and IL-13, and are involved in humoral immunity. In numerous cancers, including RCC, activated Th1 has been thought to enhance anti-tumor immune responses, in contrast to the inhibitory mechanisms of the Th2 system on innate immunity. Therefore, patients with elevated level of Th1 cells as well as Th1/Th2 ratio exhibit productive anti-cancer immune responses. In those cases, sunitinib might affect cancer cells with innate anticancer immunity synergistically. The combination of antiangiogenic therapy with immunotherapy based on an immune checkpoint blockade has been proposed as a potential new therapeutic approach for mRCC patients. Because our study demonstrated that some immunological markers possess the ability to predict the efficacy of sunitinib before treatment, these immunological markers may assist in the selection of antiangiogenic drugs in combination with immune checkpoint inhibitors before treatment.

Previous studies have demonstrated that on-treatment hypertension, thrombocytopenia and relative dose intensity are useful biomarkers to predict sunitinib efficacy. In our cohort, on-treatment hypertension and longer sunitinib treatment period predicted better survival. The prognostic value of those on-treatment markers seems promising; however, unfortunately, on-treatment markers have little impact on drug choice in the first-line setting. Therefore, we further evaluated baseline markers as prognostic indices of sunitinib treatment and found that some baseline markers have the potential to predict survival in patients with mRCC.

In summary, our results show that some angiogenic, inflammatory and immunological markers at baseline may have the potential to predict treatment response to first-line sunitinib for mRCC. The predictive ability of each marker is considerable, and these results have important implications for optimizing the care of mRCC patients.

Acknowledgments

This study was sponsored by Pfizer. The following list represents contributors and institutions involved in this study: Dr T. Yuasa of Cancer Institute Hospital of JFCR, Dr A. Horiguchi of National Defense Medical College, Dr N. Nakaigawa of Yokohama City University Hospital. Dr M. Oyama of Saitama Medical University International Medical Center, Dr H. Nagata of Saiseikai Central Hospital, Dr M. Ishida of Saiseikai Yokohama East Hospital, Dr N. Kawata of Nihon University Hospital, Dr T. Hatano of Jikei University Affiliated Kashiwa Hospital, Dr T. Kishida of Kanagawa Cancer Center, Dr J. Morita of Showa University, Dr R. Yamaguchi and Dr T. Nakagawa of Teikyo University and Dr H. Kume of Tokyo University.

Disclosure Statement

R. Mizuno reports receiving speakers’ bureau honoraria from Novartis and Pfizer. G. Kimura reports receiving speakers’ bureau honoraria from Bayer, Novartis and Pfizer and is an advisory board member for Novartis. T. Kondo reports receiving speakers’ bureau honoraria from Bayer, Novartis and Pfizer. H. Nakazawa reports receiving speakers’ bureau honoraria from Bayer, Novartis and Pfizer. S. Horie reports receiving speakers’ bureau honoraria from Bayer, Novartis and Pfizer, and a commercial research grant from Pfizer. M. Oya reports receiving speakers’ bureau honoraria from Bayer, Novartis and Pfizer, and a commercial research grant from Novartis and Pfizer. No potential conflicts of interest have been disclosed by the other authors.

References

1. Stephenson AJ, Chetner MP, Rourke K et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004; 172: 55–62.

2. Stukalin I, Alimohamed N, Heng DY. Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev 2016; 295: 19–27.

3. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24.

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
4 Porta C, Paglino C, De Amici M et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipo- 
calin in advanced kidney cancer patients receiving sunitinib. Kidney Int  
2010; 77: 809–15.
5 Porta C, Paglino C, Imrazio I et al. Changes in circulating pro-angiogenic 
cytokines, other than VEGF, before progression to sunitinib therapy in 
advanced renal cell carcinoma patients. Oncology 2013; 84: 115–22.
6 Keizman D, Ish-Shalom M, Huang P et al. The association of pre-treatment 
neutrophil to lymphocyte ratio with response rate, progression free survival 
and overall survival of patients treated with sunitinib for metastatic renal cell 
carcinoma. Eur J Cancer 2012; 48: 202–8.
7 McDermott DF, Cheng SC, Signoretti S et al. The high-dose aldesleukin 
“select” trial: a trial to prospectively validate predictive models of response 
to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res  
2015; 21: 561–8.
8 Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as 
a comparative treatment for clinical trials of new therapies against advanced 
renal cell carcinoma. J Clin Oncol 2002; 20: 289–96.
9 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation crite-
ria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer  
2009; 45: 228–47.
10 Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction 
of bone metastases by combination of tartrate-resistant acid phosphatase, 
alkaline phosphatase and prostate specific antigen in patients with prostate 
cancer. Int J Urol 2008; 15: 419–22.
11 Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol 2014; 25(Suppl 3): iii49–56.
12 Peps MB, Hirschfield GM. C-reactive protein: a critical update. J Clin 
Invest 2003; 111: 1805–12.
13 Jiang X, Hiki N, Nunobe S et al. Prognostic importance of the inflamma-
tion-based Glasgow prognostic score in patients with gastric cancer. Br J 
Cancer 2012; 107: 275–9.
14 Beuselinck B, Vano YA, Oudard S et al. Prognostic impact of baseline 
serum C-reactive protein in patients with metastatic renal cell carcinoma 
(RCC) treated with sunitinib. BJU Int 2014; 114: 81–9.
15 Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel 
potentials. Int J Cancer 2007; 121: 2373–80.
16 Fu Q, Chang Y, An H et al. Prognostic value of interleukin-6 and interleukin-6 
receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional 
cancer-specific survival analysis. Br J Cancer 2015; 113: 1581–9.
17 Altundag O, Altundag K, Gunduz E. Interleukin-6 and C-reactive protein in 
metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 1044.
18 Hoefler IE, Steffens S, Ala-Korpela M et al. Novel methodologies for bio-
marker discovery in atherosclerosis. Eur Heart J 2015; 36: 2635–42.
19 Ko YJ, Kwon YM, Kim KH et al. High-sensitivity C-reactive protein levels 
and cancer mortality. Cancer Epidemiol Biomarkers Prev 2012; 21: 2076– 
86.
20 Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 
2008; 14: 6735–41.
21 Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor 
Rev 2001; 12: 375–91.
22 Hartman ZC, Poage GM, den Hollander P et al. Growth of triple-negative 
breast cancer cells relies upon coordinate autocrine expression of the pro-
f inflamatory cytokines IL-6 and IL-8. Cancer Res 2013; 73: 3470–80.
23 Grepin R, Guyot M, Jacquin M et al. Acceleration of clear cell renal cell 
carcinoma growth in mice following bevacizumab/Avastin treatment: the role 
of CXCL cytokines. Oncogene 2012; 31: 1683–94.
24 Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal 
cytokines profile in metastatic renal cell carcinoma patients treated with sub-
cutaneous IL-2-based therapy compared with that of healthy donors. J Transl 
Med 2007; 5: 51.
25 Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangio-
genic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 
1063–71.
26 Xu CF, Johnson T, Garcia-Donas J et al. IL-8 polymorphisms and overall 
survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. 
Br J Cancer 2015; 112: 1190–8.
27 Finke J, Ko J, Rini B et al. MDSC as a mechanism of tumor escape from 
sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11: 
856–61.
28 Hamilton DH, Bretscher PA. Different immune correlates associated with 
tumor progression and regression: implications for prevention and treatment 
of cancer. Cancer Immunol Immunother 2008; 57: 1125–36.
29 Hong CC, Yao S, McCann SE et al. Pretreatment levels of circulating Th1 
and Th2 cytokines, and their ratios, are associated with ER-negative and tri-
ple negative breast cancers. Breast Cancer Res Treat 2013; 139: 477–88.
30 Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus 
in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803–13.
31 Porta C, Levy A, Hawkins R et al. Impact of adverse events, treatment mod-
fications, and dose intensity on survival among patients with advanced renal 
cell carcinoma treated with first-line sunitinib: a medical chart review across 
ten centers in five European countries. Cancer Med 2014; 3: 1517–26.
32 Kautiola J, Donskov F, Peltola K et al. Sunitinib-induced hypertension, neu-
tropenia and thrombocytopenia as predictors of good prognosis in patients 
with metastatic renal cell carcinoma. BJU Int 2016; 117: 110–7.